Eli Lilly And Co (LLY) is Private Capital Advisors Inc.’s Largest Position

Share on StockTwits

Private Capital Advisors Inc. raised its holdings in Eli Lilly And Co (NYSE:LLY) by 0.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 388,539 shares of the company’s stock after buying an additional 2,990 shares during the quarter. Eli Lilly And Co accounts for approximately 11.3% of Private Capital Advisors Inc.’s holdings, making the stock its biggest holding. Private Capital Advisors Inc.’s holdings in Eli Lilly And Co were worth $33,236,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. United Capital Financial Advisers LLC grew its holdings in shares of Eli Lilly And Co by 2.9% in the 1st quarter. United Capital Financial Advisers LLC now owns 65,183 shares of the company’s stock worth $5,043,000 after purchasing an additional 1,819 shares during the last quarter. Natixis lifted its position in Eli Lilly And Co by 52.5% during the 1st quarter. Natixis now owns 166,644 shares of the company’s stock worth $12,893,000 after buying an additional 57,354 shares in the last quarter. Freestone Capital Holdings LLC lifted its position in Eli Lilly And Co by 3.4% during the 1st quarter. Freestone Capital Holdings LLC now owns 27,316 shares of the company’s stock worth $2,113,000 after buying an additional 901 shares in the last quarter. Hilltop Holdings Inc. acquired a new position in Eli Lilly And Co during the 1st quarter worth about $288,000. Finally, Banco de Sabadell S.A lifted its position in Eli Lilly And Co by 8.7% during the 1st quarter. Banco de Sabadell S.A now owns 17,083 shares of the company’s stock worth $1,322,000 after buying an additional 1,372 shares in the last quarter. 76.56% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly And Co stock opened at $110.48 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The stock has a market cap of $115.25 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The company had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. During the same period in the prior year, the company posted $1.11 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. On average, analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current year.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 14,632 shares of the company’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $115.91, for a total transaction of $1,695,995.12. Following the transaction, the insider now directly owns 119,191,172 shares in the company, valued at approximately $13,815,448,746.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $114.64, for a total transaction of $802,480.00. Following the transaction, the senior vice president now owns 45,224 shares in the company, valued at $5,184,479.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,785,575 shares of company stock worth $180,166,130. Corporate insiders own 0.11% of the company’s stock.

Several research analysts recently issued reports on the stock. Credit Suisse Group upped their price target on shares of Eli Lilly And Co from $82.00 to $84.00 and gave the stock an “underperform” rating in a research report on Thursday, June 21st. JPMorgan Chase & Co. set a $123.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Friday, October 5th. Bank of America upped their price target on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Tuesday, July 24th. Finally, TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a research report on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $107.88.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply